암 치료 새 지평, 온열암치료기 ‘리미션1℃’ 전 세계가 주목
A new horizon in cancer treatment, the world is paying attention to hyperthermia cancer treatment device of ‘REMISSON 1℃’
【Health and Welfare News】 Domestic and international cancer treatment scholars gathered together to share the effects and clinical results of 'REMISSION 1℃', a high-frequency hyperthermia cancer treatment device that is opening a new horizon in cancer treatment, which has been applied as a cancer treatment in about 80 hospitals in Korea. The international conference will be held in Malaysia on November 25 from 9:00 to 18:00 local time.
The 5th IVRA (International Virus Research Alliance Organizing Committee Chairman Yoo Seung-mo, Director of Yesan Myeongji Hospital in South Chungcheong Province) International Conference will be held at Le Meridien Hotel in Cyber Jaya, Malaysia.
In particular, this conference will be held as an international academic seminar in which a large number of domestic and foreign IVRA organizers and members, government officials, and medical personnel will participate to present and share clinical results related to high-frequency hyperthermia therapy.
In Korea, about 20 people including Professors Jang Hong-seok and Kang Young-nam of the Department of Radiation Oncology at Seoul St. Mary's Hospital of the Catholic University of Korea, former Dean Lee Kang-hyeon of Yonsei University Wonju University, IVRA Organizing Committee Chairman Yoo Seung-mo, Dr. Kim Eui-shin (Department of Radiation Oncology), a tenured professor at MD Anderson in the U.S., Jang Sang-geun, former director of Konkuk University Hospital, and Kim Seon-man of Suwon Amirang Clinic will attend.
In addition, overseas experts in cancer treatment such as Dr. Ho Gwo Fuang, an authority on cancer treatment in Malaysia, University of Cyberjaya Chairman Kalaiarasu Malayandi, Dr. Paramjit Kaur, Dr. Jayendran Dharmaratnam, and Dr. Damodara Kumaran and Dr. Nagraj G. Huilgol from India attended to discuss cancer treatment. They present the effects and clinical results of hyperthermia treatment using 'REMISSION 1℃'.
‘REMISSION 1℃’, a high-frequency cancer treatment device, was developed by AdipoLABs Co., Ltd. (CEO Han Sung-ho) with its own technology and was approved as a cancer treatment device by the Ministry of Food and Drug Safety in 2015, and is being used to treat cancer patients at home and abroad.
AdipoLABs has been actively cooperating with overseas medical staff through various activities such as overseas sales, clinical research, and free donations.
In addition, overseas medical staff who have verified the cancer treatment effectiveness of ‘REMISSION 1℃’ have consistently conducted academic seminars to help rehabilitate and treat cancer patients around the world.
IVRA is held every year to share the effects of clinical treatment, focusing on cancer treatment which is a long-awaited goal of humanity after the COVID-19.
In particular, the 5th IVRA is expected to be a meaningful event where 18 cancer treatment experts from each country will present the results of cancer treatment using ‘REMISSION 1℃’ while strengthening international cooperation for the treatment of cancer patients.
The 5th IVRA is sponsored by the Korean Society of Thermal Medicine, Wonju Severance Christian Hospital, and the Korean Association of Emergency Medicine.
Han Sung-ho, CEO of AdipoLABs Co., Ltd., the main sponsor, said, “The cancer treatment effects of ‘REMISSION 1℃,’ a high-frequency hyperthermia cancer treatment device, have been known not only domestically but also overseas, so it is expected to serve as an opportunity to further enhance our overseas expansion.” He emphasized, “We will do our best so that ‘REMISSION 1℃’ can provide hope not only to cancer patients in Korea but also to cancer patients around the world.”
Meanwhile, this conference is expected to be an international academic conference that shares vivid treatment cases for cancer treatment, starting with a video congratulatory speech by Cha Sun-do, director of the Korea Health Industry Development Institute, followed by congratulatory speeches by IVRA Organizing Committee Chairman Yoo Seung-mo, Professor Jang Hong-seok of Seoul St. Mary's Hospital, and high-ranking Malaysian officials.
